Formulation Development Forum - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Formulation Development Forum
Analysis of crospovidone as a superdistingrant.


Pharmaceutical Technology
Volume 35, Issue 1, pp. 50

Excipient quality and performance are crucial factors in drug development and manufacturing. Excipient producers evaluate their products in given formulations to assess their utility compared with other excipients and functionality with specific active ingredients. International Specialty Products (ISP, Wayne, NJ), a producer of crospovidone, a commonly used superdisintegrant, recently launched a new ultra-pure grade of crospovidone to provide a crospovidone product with lower levels of peroxides, an important consideration in drug stability.

ISP manufactures standard pharmaceutical grades of crospovidone and launched an ultra-pure grade of crospovidone in November 2010. Crospovidone is a cross-linked homopolymer of N-vinyl-2-pyrrolidone. Peroxides result from the oxidation of crospovidone during production and storage, and their formation can be reduced by processing and packaging crospovidone under inert conditions. Although the United States Pharmacopeia does not specify peroxide limits for crospovidone, the European Pharmacopoeia does, with Type A having a limit of 400 ppm max, and the smaller particle size Type B having a limit of 1000 ppm max.

ISP's standard pharmaceutical grades of crospovidone have peroxide specification limits of 400 ppm max for both Type A and Type B products. Its new ultra-pure pharmaceutical crospovidone is available in two grades, with peroxide specifications of 30 ppm max and 50 ppm max for Type A and Type B respectively, explains Tim Bee, senior director of the global pharmaeutical technical operations at ISP.

ISP produces its ultra-pure grades of crospovidone (Polyplasdone Ultra and Ultra-10) at a new facility in Texas City, Texas, which is also one of two sites where the company manufactures its standard pharmaceutical grades of crospovidone (Polyplasdone XL and Polyplasdone XL-10). The ultra-pure grades of crospovidone are available in the same typical particle size ranges as the standard pharmaceutical grades. The ultra-purity grades have average particle sizes of 110–140 Ám (Polyplasdone Ultra) and average particle sizes of 20-30 Ám (Polyplasdone Ultra-10).

Bee explains that the lower levels of peroxides in the ultra-pure grades of crospovidone are achieved by manufacturing, drying, packing, and sealing the product under inert conditions (i.e., nitrogen) to limit peroxide formation. ISP has been manufacturing the standard pharmaceutical grades of crospovidone at its Texas City, facility since 2007, and began work on the high-purity grades in 2008. Following process improvements and optimization, the ultra-pure grades have been available on a commercial scale since November 2010. Bee explains that the ultra-pure grades of crospovidone would be beneficial for active ingredients that need the performance advantages offered by crospovidone, but may be susceptible to peroxides, which could affect drug stability and possible degradation of the drug substance.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here